Newer PET application with an old tracer: Role of18F-NaF skeletal PET/CT in oncologic practice

Radiographics

Volumn 34, Issue 5, 2014, Pages 1295-1316

  Bastawrous, Sarah ^a,b   Bhargava, Puneet ^a,b   Behnia, Fatemeh ^a   Djang, David S W ^c   Haseley, David R ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c Seattle Nuclear Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; SODIUM FLUORIDE;

BONE NEOPLASMS; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; HUMAN; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIATION DOSE;

BONE NEOPLASMS; FLUORINE RADIOISOTOPES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOPHARMACEUTICALS; SODIUM FLUORIDE; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84907060485     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.345130061     Document Type: Article

References (54)

1. Rubens RD. Bone metastases: incidence and complications. In: Mundy GR, Rubens RD. Cancer and the skeleton. London, England: Martin Dunitz, 2000; 33-42.
2. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17(8):2381-2389.
3. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962;3: 332-334.
4. 18F-fluoride for bone imaging. Semin Nucl Med 1972;2(1):31-37.
5. Hawkins RA, Hoh C, Glaspy J, et al. The role of positron emission tomography in oncology and other whole-body applications. Semin Nucl Med 1992;22(4):268-284.
6. Chilton HM, Francis MD, Thrall JH. Radiopharmaceuticals for bone and bone marrow imaging. In: Swanson DP, Chilton HM, Thrall JH, eds. Pharmaceuticals in medical imaging: radiopaque contrast media, radiopharmaceuticals, enhancement agents for magnetic resonance imaging and ultrasound. New York, NY: Macmillan, 1990;537-563.
7. 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008;49(1):68-78.
8. 18F-NaF deposition. J Nucl Med 2010;51(12):1826-1829.
9. Weber DA, Greenberg EJ, Dimich A, et al. Kinetics of radionuclides used for bone studies. J Nucl Med 1969;10(1):8-17.
10. Schlonsky J. Radioisotope scanning of bone: a review of the literature. Ohio State Med J 1972;68 (2):128-133.
11. 99mTc-methylene diphosphonate. Semin Nucl Med 2001;31(1):28-49.
12. 18F-fluoride PET/CT bone scans 1.0. J Nucl Med 2010;51(11):1813-1820.
13. 18F-NaF PET for the evaluation of bone pain in children. AJR Am J Roentgenol 2011; 197(3):713-719.
14. Hoh CK, Hawkins RA, Dahlbom M, et al. Whole body skeletal imaging with [18F]fluoride ion and PET. J Comput Assist Tomogr 1993;17(1):34-41.
15. Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am 2007;45(4):669-676, vi.
16. 18F NaF PET/CT and conventional bone scanning in routine clinical practice: comparative analysis of tracers, clinical acquisition protocols, and performance indices. PET Clin 2012;7(3):315-328.
17. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001;42 (12):1800-1804.
18. 18F NaF PET/CT in the assessment of metastatic bone disease: comparison with specific PET tracers. PET Clin 2012;7(3): 303-314.
19. 18F-fluoride PET/CT. J Nucl Med 2004;45(2):272-278.
20. 18F-fluoride PET/CT. J Nucl Med 2006;47(2): 287-297.
21. m Tc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma. Clin Nucl Med 2013;38(8):616-621.
22. Zhang Y, Shi H, Cheng D, et al. Added value of SPECT/spiral CT versus SPECT in diagnosing solitary spinal lesions in patients with extraskeletal malig-nancies. Nucl Med Commun 2013;34(5):451-458.
23. 18 F PET. J Nucl Med 1999;40(10):1623-1629.
24. Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med 2001;31(1):50-61.
25. 18 F-NaF-PET/CT in patients with chronic osteomyelitis. Ann Nucl Med 2014;28(4)314-321. http://link.springer.com/article/10.1007%2Fs12149-014-0810-4. Published online January 29, 2014. Accessed February 9, 2014.
26. 18F-NaF: mechanisms and applications. J Nucl Med 2013;54(4): 590-599.
27. 18F-fluoride positronemission tomography-computed tomography. J Pediatr Orthop 2007;27(1):90-93.
28. 18F-NaF PET. Radiology 2010;255(1):173-181.
29. Drubach LA, Sapp MV, Laffin S, Kleinman PK. Fluorine-18 NaF PET imaging of child abuse. Pediatr Radiol 2008;38(7):776-779.
30. 18 F-fluoride PET. Eur J Nucl Med Mol Imaging 2004;31(9):1291-1298.
31. Piert M, Winter E, Becker GA, et al. Allogenic bone graft viability after hip revision arthroplasty assessed by dynamic [18F]fluoride ion positron emission tomography. Eur J Nucl Med 1999;26(6):615-624.
32. Ullmark G, Sundgren K, Milbrink J, Nilsson O, Sörensen J. Osteonecrosis following resurfacing arthroplasty. Acta Orthop 2009;80(6):670-674.
33. Schiepers C, Broos P, Miserez M, Bormans G, De Roo M. Measurement of skeletal flow with positron emission tomography and 18F-fluoride in femoral head osteonecrosis. Arch Orthop Trauma Surg 1998;118(3):131-135.
34. 18F-FDG PET scans to assess fracture healing in a rat femur model. Eur J Nucl Med Mol Imaging 2007;34(8):1291-1301.
35. 18F-fluoride PET for monitoring therapeutic response in Paget’s disease of bone. J Nucl Med 2005;46(10):1650-1658.
36. Messa C, Goodman WG, Hoh CK, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab 1993;77(4):949-955.
37. 18F-fluoride positron emission tomography. J Bone Miner Res 2002; 17(5):854-859.
38. 18F-fluoride PET. Eur J Nucl Med Mol Imaging 2011;38(5):884-893.
39. 18F-fluoride positron emission tomography. J Bone Miner Res 2003;18(12):2215-2222.
40. 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turn-over. J Clin Densitom 2007;10(1):46-54.
41. 18F-fluoride PET, and vascular calcification in atherosclerotic plaque: a dual-tracer PET/CT study. J Nucl Med 2011;52(7): 1020-1027.
42. 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol 1998;27(2):72-76.
43. 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006;36(1):73-92.
44. Smith GT. F-18 sodium fluoride PET imaging. Webinar presented by SNM: Society of Nuclear Medicine and Molecular Imaging. http://webinars.snm.org/viewer.php?meeting_id=8022110&brand_url=http://webinars.snm.org/. Published 2010. Accessed July 16, 3013.
45. 18F-fluoride PET scans. J Nucl Med 2004;45(9):1493-1500.
46. 18F-sodium fluoride uptake as a marker of plaque biology. Expert Rev Cardiovasc Ther 2012;10(9):1075-1077.
47. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005;46(8):1356-1367.
48. Cook GJ, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med 1999;29(1):69-79.
49. Hetzel M, Arslandemir C, König HH, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 2003;18 (12):2206-2214.
50. 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009;36(11):1807-1812.
51. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology 1998;209 (1):253-258.
52. 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med 2009;50(4):501-505.
53. 18F-FDG PET/CT imaging for detection of malignancy. Eur J Nucl Med Mol Imaging 2012;39 (2):262-270.
54. Palmedo H, Grohé C, Ko Y, Tasci S. PET and PET/ CT with F-18 fluoride in bone metastases. Recent Results Cancer Res 2008;170:213-224.